nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A5—Beclomethasone—psoriasis	0.0731	0.103	CbGbCtD
Ondansetron—CYP1A2—Clobetasol propionate—psoriasis	0.0718	0.102	CbGbCtD
Ondansetron—CYP1A2—Methoxsalen—psoriasis	0.0377	0.0534	CbGbCtD
Ondansetron—CYP2D6—Hydroxyurea—psoriasis	0.034	0.0481	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0311	0.044	CbGbCtD
Ondansetron—CYP3A7—Hydrocortisone—psoriasis	0.0311	0.044	CbGbCtD
Ondansetron—CYP3A7—Cyclosporine—psoriasis	0.0294	0.0416	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0294	0.0416	CbGbCtD
Ondansetron—CYP3A5—Mycophenolate mofetil—psoriasis	0.0291	0.0412	CbGbCtD
Ondansetron—CYP3A4—Calcitriol—psoriasis	0.0254	0.0359	CbGbCtD
Ondansetron—CYP3A5—Hydrocortisone—psoriasis	0.0234	0.033	CbGbCtD
Ondansetron—CYP2C9—Cholecalciferol—psoriasis	0.0225	0.0318	CbGbCtD
Ondansetron—CYP3A5—Cyclosporine—psoriasis	0.0221	0.0312	CbGbCtD
Ondansetron—CYP2D6—Cholecalciferol—psoriasis	0.0206	0.0291	CbGbCtD
Ondansetron—CYP3A4—Methoxsalen—psoriasis	0.0198	0.028	CbGbCtD
Ondansetron—CYP3A7—Dexamethasone—psoriasis	0.0194	0.0274	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0194	0.0274	CbGbCtD
Ondansetron—CYP2E1—Dexamethasone—psoriasis	0.0187	0.0264	CbGbCtD
Ondansetron—CYP2C9—Cyclosporine—psoriasis	0.0148	0.0209	CbGbCtD
Ondansetron—CYP3A5—Dexamethasone—psoriasis	0.0145	0.0205	CbGbCtD
Ondansetron—CYP2D6—Cyclosporine—psoriasis	0.0135	0.0191	CbGbCtD
Ondansetron—CYP3A4—Cholecalciferol—psoriasis	0.0131	0.0185	CbGbCtD
Ondansetron—CYP3A4—Mycophenolate mofetil—psoriasis	0.0113	0.0161	CbGbCtD
Ondansetron—CYP3A4—Triamcinolone—psoriasis	0.0113	0.0161	CbGbCtD
Ondansetron—CYP2C9—Dexamethasone—psoriasis	0.00974	0.0138	CbGbCtD
Ondansetron—CYP3A4—Betamethasone—psoriasis	0.00974	0.0138	CbGbCtD
Ondansetron—CYP3A4—Prednisolone—psoriasis	0.00961	0.0136	CbGbCtD
Ondansetron—CYP3A4—Hydrocortisone—psoriasis	0.00911	0.0129	CbGbCtD
Ondansetron—CYP3A4—Prednisone—psoriasis	0.00907	0.0128	CbGbCtD
Ondansetron—CYP2D6—Dexamethasone—psoriasis	0.00891	0.0126	CbGbCtD
Ondansetron—CYP3A4—Cyclosporine—psoriasis	0.0086	0.0122	CbGbCtD
Ondansetron—CYP3A4—Dexamethasone—psoriasis	0.00566	0.00801	CbGbCtD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—CP—psoriasis	0.000279	0.00579	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—HCAR2—psoriasis	0.000273	0.00567	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—CCL20—psoriasis	0.00027	0.0056	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HCAR2—psoriasis	0.000266	0.00553	CbGpPWpGaD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000266	0.00553	CbGpPWpGaD
Ondansetron—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000263	0.00545	CbGpPWpGaD
Ondansetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.00538	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000257	0.00534	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000251	0.00522	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	0.000248	0.00514	CbGpPWpGaD
Ondansetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000246	0.00512	CbGpPWpGaD
Ondansetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000244	0.00507	CbGpPWpGaD
Ondansetron—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000243	0.00505	CbGpPWpGaD
Ondansetron—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000236	0.00489	CbGpPWpGaD
Ondansetron—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000229	0.00476	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000229	0.00475	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000228	0.00474	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000226	0.00468	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000225	0.00467	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—IL10—psoriasis	0.000224	0.00464	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000217	0.00451	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—HCAR2—psoriasis	0.000217	0.00451	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0002	0.00415	CbGpPWpGaD
Ondansetron—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000197	0.0041	CbGpPWpGaD
Ondansetron—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000197	0.00409	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000197	0.00409	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000195	0.00404	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000191	0.00398	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CCL20—psoriasis	0.000186	0.00387	CbGpPWpGaD
Ondansetron—Shock—Prednisolone—psoriasis	0.000182	0.000745	CcSEcCtD
Ondansetron—Cough—Triamcinolone—psoriasis	0.000182	0.000744	CcSEcCtD
Ondansetron—Dyspnoea—Cyclosporine—psoriasis	0.000182	0.000742	CcSEcCtD
Ondansetron—Somnolence—Cyclosporine—psoriasis	0.000181	0.000739	CcSEcCtD
Ondansetron—Anaphylactic shock—Hydrocortisone—psoriasis	0.000181	0.000739	CcSEcCtD
Ondansetron—Convulsion—Triamcinolone—psoriasis	0.000181	0.000739	CcSEcCtD
Ondansetron—Tachycardia—Prednisolone—psoriasis	0.000181	0.000739	CcSEcCtD
Ondansetron—Asthenia—Mycophenolic acid—psoriasis	0.000181	0.000738	CcSEcCtD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—CP—psoriasis	0.00018	0.00373	CbGpPWpGaD
Ondansetron—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000179	0.000729	CcSEcCtD
Ondansetron—Pruritus—Mycophenolic acid—psoriasis	0.000178	0.000727	CcSEcCtD
Ondansetron—Shock—Hydrocortisone—psoriasis	0.000178	0.000727	CcSEcCtD
Ondansetron—Nervous system disorder—Hydrocortisone—psoriasis	0.000178	0.000725	CcSEcCtD
Ondansetron—Eye disorder—Prednisone—psoriasis	0.000177	0.000723	CcSEcCtD
Ondansetron—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000177	0.000723	CcSEcCtD
Ondansetron—Tachycardia—Hydrocortisone—psoriasis	0.000177	0.000721	CcSEcCtD
Ondansetron—Somnolence—Mycophenolate mofetil—psoriasis	0.000177	0.000721	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—psoriasis	0.000177	0.000721	CcSEcCtD
Ondansetron—Flushing—Prednisone—psoriasis	0.000176	0.000719	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000176	0.000718	CcSEcCtD
Ondansetron—Skin disorder—Hydrocortisone—psoriasis	0.000176	0.000718	CcSEcCtD
Ondansetron—Ill-defined disorder—Dexamethasone—psoriasis	0.000176	0.000718	CcSEcCtD
Ondansetron—Ill-defined disorder—Betamethasone—psoriasis	0.000176	0.000718	CcSEcCtD
Ondansetron—Discomfort—Triamcinolone—psoriasis	0.000176	0.000717	CcSEcCtD
Ondansetron—Fatigue—Cyclosporine—psoriasis	0.000176	0.000717	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000175	0.000715	CcSEcCtD
Ondansetron—Pain—Cyclosporine—psoriasis	0.000174	0.000711	CcSEcCtD
Ondansetron—Constipation—Cyclosporine—psoriasis	0.000174	0.000711	CcSEcCtD
Ondansetron—Dry mouth—Triamcinolone—psoriasis	0.000174	0.00071	CcSEcCtD
Ondansetron—Angioedema—Betamethasone—psoriasis	0.000173	0.000707	CcSEcCtD
Ondansetron—Angioedema—Dexamethasone—psoriasis	0.000173	0.000707	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.000173	0.00359	CbGpPWpGaD
Ondansetron—Diarrhoea—Mycophenolic acid—psoriasis	0.000172	0.000703	CcSEcCtD
Ondansetron—Angiopathy—Prednisone—psoriasis	0.000172	0.000702	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000172	0.000701	CcSEcCtD
Ondansetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000172	0.00356	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000171	0.00356	CbGpPWpGaD
Ondansetron—Immune system disorder—Prednisone—psoriasis	0.000171	0.000699	CcSEcCtD
Ondansetron—Malaise—Dexamethasone—psoriasis	0.000171	0.000698	CcSEcCtD
Ondansetron—Malaise—Betamethasone—psoriasis	0.000171	0.000698	CcSEcCtD
Ondansetron—Anaphylactic shock—Triamcinolone—psoriasis	0.000171	0.000696	CcSEcCtD
Ondansetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00017	0.00353	CbGpPWpGaD
Ondansetron—Syncope—Dexamethasone—psoriasis	0.00017	0.000694	CcSEcCtD
Ondansetron—Syncope—Betamethasone—psoriasis	0.00017	0.000694	CcSEcCtD
Ondansetron—Constipation—Mycophenolate mofetil—psoriasis	0.00017	0.000694	CcSEcCtD
Ondansetron—Pain—Mycophenolate mofetil—psoriasis	0.00017	0.000694	CcSEcCtD
Ondansetron—Arrhythmia—Prednisone—psoriasis	0.000169	0.000692	CcSEcCtD
Ondansetron—Hypotension—Hydrocortisone—psoriasis	0.000169	0.000691	CcSEcCtD
Ondansetron—Feeling abnormal—Cyclosporine—psoriasis	0.000168	0.000685	CcSEcCtD
Ondansetron—Shock—Triamcinolone—psoriasis	0.000168	0.000685	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—psoriasis	0.000167	0.000682	CcSEcCtD
Ondansetron—Gastrointestinal pain—Cyclosporine—psoriasis	0.000167	0.00068	CcSEcCtD
Ondansetron—Loss of consciousness—Dexamethasone—psoriasis	0.000167	0.00068	CcSEcCtD
Ondansetron—Loss of consciousness—Betamethasone—psoriasis	0.000167	0.00068	CcSEcCtD
Ondansetron—Dizziness—Mycophenolic acid—psoriasis	0.000167	0.00068	CcSEcCtD
Ondansetron—Paraesthesia—Prednisolone—psoriasis	0.000167	0.00068	CcSEcCtD
Ondansetron—Tachycardia—Triamcinolone—psoriasis	0.000166	0.000679	CcSEcCtD
Ondansetron—HTR1A—GPCR ligand binding—HCAR2—psoriasis	0.000165	0.00343	CbGpPWpGaD
Ondansetron—Erythema—Prednisone—psoriasis	0.000165	0.000674	CcSEcCtD
Ondansetron—Convulsion—Dexamethasone—psoriasis	0.000164	0.00067	CcSEcCtD
Ondansetron—Convulsion—Betamethasone—psoriasis	0.000164	0.00067	CcSEcCtD
Ondansetron—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000164	0.00341	CbGpPWpGaD
Ondansetron—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000164	0.000669	CcSEcCtD
Ondansetron—Paraesthesia—Hydrocortisone—psoriasis	0.000163	0.000664	CcSEcCtD
Ondansetron—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000163	0.000664	CcSEcCtD
Ondansetron—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000162	0.00337	CbGpPWpGaD
Ondansetron—Urticaria—Cyclosporine—psoriasis	0.000162	0.000661	CcSEcCtD
Ondansetron—Abdominal pain—Cyclosporine—psoriasis	0.000161	0.000658	CcSEcCtD
Ondansetron—Body temperature increased—Cyclosporine—psoriasis	0.000161	0.000658	CcSEcCtD
Ondansetron—Anxiety—Betamethasone—psoriasis	0.000161	0.000657	CcSEcCtD
Ondansetron—Anxiety—Dexamethasone—psoriasis	0.000161	0.000657	CcSEcCtD
Ondansetron—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000161	0.00334	CbGpPWpGaD
Ondansetron—Vomiting—Mycophenolic acid—psoriasis	0.00016	0.000654	CcSEcCtD
Ondansetron—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00016	0.00332	CbGpPWpGaD
Ondansetron—Discomfort—Dexamethasone—psoriasis	0.00016	0.000651	CcSEcCtD
Ondansetron—Discomfort—Betamethasone—psoriasis	0.00016	0.000651	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—psoriasis	0.000159	0.00065	CcSEcCtD
Ondansetron—Rash—Mycophenolic acid—psoriasis	0.000159	0.000648	CcSEcCtD
Ondansetron—Dermatitis—Mycophenolic acid—psoriasis	0.000159	0.000648	CcSEcCtD
Ondansetron—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000159	0.0033	CbGpPWpGaD
Ondansetron—Pain—Prednisolone—psoriasis	0.000159	0.000647	CcSEcCtD
Ondansetron—Haemorrhage—Methotrexate—psoriasis	0.000159	0.000647	CcSEcCtD
Ondansetron—Urticaria—Mycophenolate mofetil—psoriasis	0.000158	0.000645	CcSEcCtD
Ondansetron—Headache—Mycophenolic acid—psoriasis	0.000158	0.000644	CcSEcCtD
Ondansetron—HTR4—Signaling Pathways—HCAR2—psoriasis	0.000157	0.00327	CbGpPWpGaD
Ondansetron—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000157	0.00327	CbGpPWpGaD
Ondansetron—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000157	0.000641	CcSEcCtD
Ondansetron—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000157	0.000641	CcSEcCtD
Ondansetron—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000156	0.00325	CbGpPWpGaD
Ondansetron—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000156	0.000638	CcSEcCtD
Ondansetron—Fatigue—Hydrocortisone—psoriasis	0.000156	0.000637	CcSEcCtD
Ondansetron—Vision blurred—Prednisone—psoriasis	0.000156	0.000635	CcSEcCtD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000155	0.00323	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000155	0.00322	CbGpPWpGaD
Ondansetron—Pain—Hydrocortisone—psoriasis	0.000155	0.000632	CcSEcCtD
Ondansetron—Anaphylactic shock—Betamethasone—psoriasis	0.000155	0.000632	CcSEcCtD
Ondansetron—Anaphylactic shock—Dexamethasone—psoriasis	0.000155	0.000632	CcSEcCtD
Ondansetron—Ill-defined disorder—Prednisone—psoriasis	0.000153	0.000625	CcSEcCtD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000153	0.00318	CbGpPWpGaD
Ondansetron—Paraesthesia—Triamcinolone—psoriasis	0.000153	0.000625	CcSEcCtD
Ondansetron—Feeling abnormal—Prednisolone—psoriasis	0.000153	0.000624	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—psoriasis	0.000153	0.000624	CcSEcCtD
Ondansetron—HTR4—GPCR downstream signaling—CCL20—psoriasis	0.000152	0.00317	CbGpPWpGaD
Ondansetron—Shock—Betamethasone—psoriasis	0.000152	0.000621	CcSEcCtD
Ondansetron—Shock—Dexamethasone—psoriasis	0.000152	0.000621	CcSEcCtD
Ondansetron—Dyspnoea—Triamcinolone—psoriasis	0.000152	0.000621	CcSEcCtD
Ondansetron—Nervous system disorder—Betamethasone—psoriasis	0.000152	0.000619	CcSEcCtD
Ondansetron—Nervous system disorder—Dexamethasone—psoriasis	0.000152	0.000619	CcSEcCtD
Ondansetron—Agitation—Prednisone—psoriasis	0.000152	0.000619	CcSEcCtD
Ondansetron—Tachycardia—Betamethasone—psoriasis	0.000151	0.000616	CcSEcCtD
Ondansetron—Tachycardia—Dexamethasone—psoriasis	0.000151	0.000616	CcSEcCtD
Ondansetron—Angioedema—Prednisone—psoriasis	0.000151	0.000616	CcSEcCtD
Ondansetron—Hypersensitivity—Cyclosporine—psoriasis	0.00015	0.000613	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—psoriasis	0.00015	0.000612	CcSEcCtD
Ondansetron—Feeling abnormal—Hydrocortisone—psoriasis	0.000149	0.000609	CcSEcCtD
Ondansetron—Malaise—Prednisone—psoriasis	0.000149	0.000608	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—psoriasis	0.000148	0.000605	CcSEcCtD
Ondansetron—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000148	0.000604	CcSEcCtD
Ondansetron—Syncope—Prednisone—psoriasis	0.000148	0.000604	CcSEcCtD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000148	0.00307	CbGpPWpGaD
Ondansetron—Urticaria—Prednisolone—psoriasis	0.000147	0.000601	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—psoriasis	0.000147	0.0006	CcSEcCtD
Ondansetron—Fatigue—Triamcinolone—psoriasis	0.000147	0.0006	CcSEcCtD
Ondansetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000147	0.00305	CbGpPWpGaD
Ondansetron—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000146	0.000598	CcSEcCtD
Ondansetron—Asthenia—Cyclosporine—psoriasis	0.000146	0.000597	CcSEcCtD
Ondansetron—Pain—Triamcinolone—psoriasis	0.000146	0.000595	CcSEcCtD
Ondansetron—Loss of consciousness—Prednisone—psoriasis	0.000145	0.000592	CcSEcCtD
Ondansetron—Hypotension—Dexamethasone—psoriasis	0.000145	0.00059	CcSEcCtD
Ondansetron—Hypotension—Betamethasone—psoriasis	0.000145	0.00059	CcSEcCtD
Ondansetron—Pruritus—Cyclosporine—psoriasis	0.000144	0.000588	CcSEcCtD
Ondansetron—Urticaria—Hydrocortisone—psoriasis	0.000144	0.000587	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—psoriasis	0.000144	0.000587	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—psoriasis	0.000143	0.000584	CcSEcCtD
Ondansetron—Abdominal pain—Hydrocortisone—psoriasis	0.000143	0.000584	CcSEcCtD
Ondansetron—Body temperature increased—Hydrocortisone—psoriasis	0.000143	0.000584	CcSEcCtD
Ondansetron—Convulsion—Prednisone—psoriasis	0.000143	0.000584	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—psoriasis	0.000143	0.000583	CcSEcCtD
Ondansetron—Asthenia—Mycophenolate mofetil—psoriasis	0.000143	0.000582	CcSEcCtD
Ondansetron—Chills—Methotrexate—psoriasis	0.000142	0.000581	CcSEcCtD
Ondansetron—HTR1A—G alpha (i) signalling events—CCL20—psoriasis	0.000142	0.00294	CbGpPWpGaD
Ondansetron—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	0.000141	0.00294	CbGpPWpGaD
Ondansetron—Pruritus—Mycophenolate mofetil—psoriasis	0.000141	0.000574	CcSEcCtD
Ondansetron—Feeling abnormal—Triamcinolone—psoriasis	0.000141	0.000574	CcSEcCtD
Ondansetron—Anxiety—Prednisone—psoriasis	0.00014	0.000572	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00014	0.00057	CcSEcCtD
Ondansetron—Diarrhoea—Cyclosporine—psoriasis	0.000139	0.000569	CcSEcCtD
Ondansetron—Paraesthesia—Betamethasone—psoriasis	0.000139	0.000567	CcSEcCtD
Ondansetron—Paraesthesia—Dexamethasone—psoriasis	0.000139	0.000567	CcSEcCtD
Ondansetron—Discomfort—Prednisone—psoriasis	0.000139	0.000567	CcSEcCtD
Ondansetron—HTR4—Signaling by GPCR—CCL20—psoriasis	0.000138	0.00287	CbGpPWpGaD
Ondansetron—Erythema—Methotrexate—psoriasis	0.000138	0.000563	CcSEcCtD
Ondansetron—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000137	0.00286	CbGpPWpGaD
Ondansetron—Hypersensitivity—Prednisolone—psoriasis	0.000137	0.000558	CcSEcCtD
Ondansetron—HTR4—Signaling Pathways—TAGAP—psoriasis	0.000136	0.00283	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—CP—psoriasis	0.000136	0.00283	CbGpPWpGaD
Ondansetron—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000136	0.000555	CcSEcCtD
Ondansetron—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00282	CbGpPWpGaD
Ondansetron—Urticaria—Triamcinolone—psoriasis	0.000136	0.000553	CcSEcCtD
Ondansetron—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000135	0.00281	CbGpPWpGaD
Ondansetron—Body temperature increased—Triamcinolone—psoriasis	0.000135	0.00055	CcSEcCtD
Ondansetron—Dizziness—Cyclosporine—psoriasis	0.000135	0.00055	CcSEcCtD
Ondansetron—Anaphylactic shock—Prednisone—psoriasis	0.000135	0.00055	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	0.000134	0.00278	CbGpPWpGaD
Ondansetron—Gastrointestinal disorder—Betamethasone—psoriasis	0.000134	0.000545	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000134	0.000545	CcSEcCtD
Ondansetron—Hypersensitivity—Hydrocortisone—psoriasis	0.000133	0.000545	CcSEcCtD
Ondansetron—Fatigue—Dexamethasone—psoriasis	0.000133	0.000545	CcSEcCtD
Ondansetron—Fatigue—Betamethasone—psoriasis	0.000133	0.000545	CcSEcCtD
Ondansetron—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000133	0.00277	CbGpPWpGaD
Ondansetron—Shock—Prednisone—psoriasis	0.000133	0.000541	CcSEcCtD
Ondansetron—Pain—Betamethasone—psoriasis	0.000132	0.00054	CcSEcCtD
Ondansetron—Pain—Dexamethasone—psoriasis	0.000132	0.00054	CcSEcCtD
Ondansetron—Nervous system disorder—Prednisone—psoriasis	0.000132	0.000539	CcSEcCtD
Ondansetron—Tachycardia—Prednisone—psoriasis	0.000132	0.000537	CcSEcCtD
Ondansetron—Dizziness—Mycophenolate mofetil—psoriasis	0.000131	0.000537	CcSEcCtD
Ondansetron—Skin disorder—Prednisone—psoriasis	0.000131	0.000534	CcSEcCtD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000131	0.00271	CbGpPWpGaD
Ondansetron—Vision blurred—Methotrexate—psoriasis	0.00013	0.000531	CcSEcCtD
Ondansetron—Asthenia—Hydrocortisone—psoriasis	0.00013	0.00053	CcSEcCtD
Ondansetron—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	0.00013	0.0027	CbGpPWpGaD
Ondansetron—Vomiting—Cyclosporine—psoriasis	0.00013	0.000529	CcSEcCtD
Ondansetron—Rash—Cyclosporine—psoriasis	0.000129	0.000524	CcSEcCtD
Ondansetron—Dermatitis—Cyclosporine—psoriasis	0.000128	0.000524	CcSEcCtD
Ondansetron—Pruritus—Hydrocortisone—psoriasis	0.000128	0.000523	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—psoriasis	0.000128	0.000523	CcSEcCtD
Ondansetron—Headache—Cyclosporine—psoriasis	0.000128	0.000521	CcSEcCtD
Ondansetron—Feeling abnormal—Betamethasone—psoriasis	0.000128	0.00052	CcSEcCtD
Ondansetron—Feeling abnormal—Dexamethasone—psoriasis	0.000128	0.00052	CcSEcCtD
Ondansetron—Gastrointestinal pain—Betamethasone—psoriasis	0.000127	0.000516	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dexamethasone—psoriasis	0.000127	0.000516	CcSEcCtD
Ondansetron—Vomiting—Mycophenolate mofetil—psoriasis	0.000126	0.000516	CcSEcCtD
Ondansetron—Hypersensitivity—Triamcinolone—psoriasis	0.000126	0.000513	CcSEcCtD
Ondansetron—Rash—Mycophenolate mofetil—psoriasis	0.000125	0.000512	CcSEcCtD
Ondansetron—Dermatitis—Mycophenolate mofetil—psoriasis	0.000125	0.000511	CcSEcCtD
Ondansetron—Headache—Mycophenolate mofetil—psoriasis	0.000125	0.000508	CcSEcCtD
Ondansetron—Malaise—Methotrexate—psoriasis	0.000124	0.000508	CcSEcCtD
Ondansetron—Diarrhoea—Hydrocortisone—psoriasis	0.000124	0.000506	CcSEcCtD
Ondansetron—Urticaria—Dexamethasone—psoriasis	0.000123	0.000502	CcSEcCtD
Ondansetron—Urticaria—Betamethasone—psoriasis	0.000123	0.000502	CcSEcCtD
Ondansetron—Dizziness—Prednisolone—psoriasis	0.000123	0.000501	CcSEcCtD
Ondansetron—HTR1B—GPCR downstream signaling—HCAR2—psoriasis	0.000123	0.00255	CbGpPWpGaD
Ondansetron—Asthenia—Triamcinolone—psoriasis	0.000122	0.000499	CcSEcCtD
Ondansetron—Body temperature increased—Betamethasone—psoriasis	0.000122	0.000499	CcSEcCtD
Ondansetron—Abdominal pain—Betamethasone—psoriasis	0.000122	0.000499	CcSEcCtD
Ondansetron—Body temperature increased—Dexamethasone—psoriasis	0.000122	0.000499	CcSEcCtD
Ondansetron—Abdominal pain—Dexamethasone—psoriasis	0.000122	0.000499	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000122	0.00254	CbGpPWpGaD
Ondansetron—Paraesthesia—Prednisone—psoriasis	0.000121	0.000494	CcSEcCtD
Ondansetron—Pruritus—Triamcinolone—psoriasis	0.000121	0.000492	CcSEcCtD
Ondansetron—Cough—Methotrexate—psoriasis	0.00012	0.000491	CcSEcCtD
Ondansetron—Dizziness—Hydrocortisone—psoriasis	0.00012	0.000489	CcSEcCtD
Ondansetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00012	0.00248	CbGpPWpGaD
Ondansetron—Convulsion—Methotrexate—psoriasis	0.00012	0.000488	CcSEcCtD
Ondansetron—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000119	0.00246	CbGpPWpGaD
Ondansetron—Chest pain—Methotrexate—psoriasis	0.000118	0.00048	CcSEcCtD
Ondansetron—Rash—Prednisolone—psoriasis	0.000117	0.000477	CcSEcCtD
Ondansetron—Dermatitis—Prednisolone—psoriasis	0.000117	0.000477	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000117	0.000476	CcSEcCtD
Ondansetron—Fatigue—Prednisone—psoriasis	0.000116	0.000474	CcSEcCtD
Ondansetron—Headache—Prednisolone—psoriasis	0.000116	0.000474	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—psoriasis	0.000116	0.000474	CcSEcCtD
Ondansetron—Constipation—Prednisone—psoriasis	0.000115	0.00047	CcSEcCtD
Ondansetron—Vomiting—Hydrocortisone—psoriasis	0.000115	0.00047	CcSEcCtD
Ondansetron—Rash—Hydrocortisone—psoriasis	0.000114	0.000466	CcSEcCtD
Ondansetron—Dermatitis—Hydrocortisone—psoriasis	0.000114	0.000466	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	0.000114	0.00236	CbGpPWpGaD
Ondansetron—Headache—Hydrocortisone—psoriasis	0.000113	0.000463	CcSEcCtD
Ondansetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000113	0.00235	CbGpPWpGaD
Ondansetron—Dizziness—Triamcinolone—psoriasis	0.000113	0.00046	CcSEcCtD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000113	0.00234	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCL20—psoriasis	0.000113	0.00234	CbGpPWpGaD
Ondansetron—Anaphylactic shock—Methotrexate—psoriasis	0.000113	0.00046	CcSEcCtD
Ondansetron—HTR1B—Signaling by GPCR—HCAR2—psoriasis	0.000111	0.00231	CbGpPWpGaD
Ondansetron—Feeling abnormal—Prednisone—psoriasis	0.000111	0.000453	CcSEcCtD
Ondansetron—Asthenia—Betamethasone—psoriasis	0.000111	0.000453	CcSEcCtD
Ondansetron—Asthenia—Dexamethasone—psoriasis	0.000111	0.000453	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—psoriasis	0.00011	0.000451	CcSEcCtD
Ondansetron—Gastrointestinal pain—Prednisone—psoriasis	0.00011	0.00045	CcSEcCtD
Ondansetron—Pruritus—Dexamethasone—psoriasis	0.000109	0.000447	CcSEcCtD
Ondansetron—Pruritus—Betamethasone—psoriasis	0.000109	0.000447	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—psoriasis	0.000109	0.000446	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000109	0.00227	CbGpPWpGaD
Ondansetron—Vomiting—Triamcinolone—psoriasis	0.000108	0.000443	CcSEcCtD
Ondansetron—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	0.000108	0.00225	CbGpPWpGaD
Ondansetron—Rash—Triamcinolone—psoriasis	0.000108	0.000439	CcSEcCtD
Ondansetron—Dermatitis—Triamcinolone—psoriasis	0.000107	0.000438	CcSEcCtD
Ondansetron—Urticaria—Prednisone—psoriasis	0.000107	0.000437	CcSEcCtD
Ondansetron—Headache—Triamcinolone—psoriasis	0.000107	0.000436	CcSEcCtD
Ondansetron—Body temperature increased—Prednisone—psoriasis	0.000107	0.000435	CcSEcCtD
Ondansetron—Abdominal pain—Prednisone—psoriasis	0.000107	0.000435	CcSEcCtD
Ondansetron—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000106	0.0022	CbGpPWpGaD
Ondansetron—Diarrhoea—Betamethasone—psoriasis	0.000106	0.000432	CcSEcCtD
Ondansetron—Diarrhoea—Dexamethasone—psoriasis	0.000106	0.000432	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—psoriasis	0.000105	0.00043	CcSEcCtD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00217	CbGpPWpGaD
Ondansetron—Dizziness—Dexamethasone—psoriasis	0.000102	0.000418	CcSEcCtD
Ondansetron—Dizziness—Betamethasone—psoriasis	0.000102	0.000418	CcSEcCtD
Ondansetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000102	0.00212	CbGpPWpGaD
Ondansetron—Paraesthesia—Methotrexate—psoriasis	0.000101	0.000413	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—psoriasis	0.0001	0.00041	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—psoriasis	0.0001	0.000409	CcSEcCtD
Ondansetron—OPRM1—GPCR ligand binding—CCL20—psoriasis	9.95e-05	0.00207	CbGpPWpGaD
Ondansetron—Hypersensitivity—Prednisone—psoriasis	9.93e-05	0.000405	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—CD4—psoriasis	9.93e-05	0.00206	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	9.93e-05	0.00206	CbGpPWpGaD
Ondansetron—Vomiting—Betamethasone—psoriasis	9.84e-05	0.000402	CcSEcCtD
Ondansetron—Vomiting—Dexamethasone—psoriasis	9.84e-05	0.000402	CcSEcCtD
Ondansetron—OPRM1—Signaling by GPCR—HCAR2—psoriasis	9.83e-05	0.00204	CbGpPWpGaD
Ondansetron—Rash—Betamethasone—psoriasis	9.76e-05	0.000398	CcSEcCtD
Ondansetron—Rash—Dexamethasone—psoriasis	9.76e-05	0.000398	CcSEcCtD
Ondansetron—Dermatitis—Betamethasone—psoriasis	9.75e-05	0.000398	CcSEcCtD
Ondansetron—Dermatitis—Dexamethasone—psoriasis	9.75e-05	0.000398	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—psoriasis	9.72e-05	0.000397	CcSEcCtD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL10—psoriasis	9.72e-05	0.00202	CbGpPWpGaD
Ondansetron—Fatigue—Methotrexate—psoriasis	9.71e-05	0.000396	CcSEcCtD
Ondansetron—Headache—Betamethasone—psoriasis	9.7e-05	0.000396	CcSEcCtD
Ondansetron—Headache—Dexamethasone—psoriasis	9.7e-05	0.000396	CcSEcCtD
Ondansetron—Asthenia—Prednisone—psoriasis	9.67e-05	0.000395	CcSEcCtD
Ondansetron—Pain—Methotrexate—psoriasis	9.63e-05	0.000393	CcSEcCtD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.57e-05	0.00199	CbGpPWpGaD
Ondansetron—Pruritus—Prednisone—psoriasis	9.54e-05	0.000389	CcSEcCtD
Ondansetron—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.36e-05	0.00194	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HCAR2—psoriasis	9.34e-05	0.00194	CbGpPWpGaD
Ondansetron—Feeling abnormal—Methotrexate—psoriasis	9.28e-05	0.000379	CcSEcCtD
Ondansetron—Diarrhoea—Prednisone—psoriasis	9.22e-05	0.000376	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—psoriasis	9.21e-05	0.000376	CcSEcCtD
Ondansetron—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.15e-05	0.0019	CbGpPWpGaD
Ondansetron—Urticaria—Methotrexate—psoriasis	8.95e-05	0.000365	CcSEcCtD
Ondansetron—Dizziness—Prednisone—psoriasis	8.91e-05	0.000364	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—psoriasis	8.9e-05	0.000363	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—psoriasis	8.9e-05	0.000363	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—JUN—psoriasis	8.89e-05	0.00185	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCL20—psoriasis	8.58e-05	0.00178	CbGpPWpGaD
Ondansetron—Vomiting—Prednisone—psoriasis	8.57e-05	0.00035	CcSEcCtD
Ondansetron—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	8.55e-05	0.00178	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	8.51e-05	0.00177	CbGpPWpGaD
Ondansetron—Rash—Prednisone—psoriasis	8.5e-05	0.000347	CcSEcCtD
Ondansetron—Dermatitis—Prednisone—psoriasis	8.49e-05	0.000346	CcSEcCtD
Ondansetron—HTR1A—Signaling by GPCR—HCAR2—psoriasis	8.48e-05	0.00176	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.47e-05	0.00176	CbGpPWpGaD
Ondansetron—Headache—Prednisone—psoriasis	8.44e-05	0.000345	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—psoriasis	8.3e-05	0.000339	CcSEcCtD
Ondansetron—HTR4—Signaling Pathways—CCL20—psoriasis	8.18e-05	0.0017	CbGpPWpGaD
Ondansetron—Asthenia—Methotrexate—psoriasis	8.08e-05	0.00033	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—psoriasis	7.97e-05	0.000325	CcSEcCtD
Ondansetron—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.93e-05	0.00165	CbGpPWpGaD
Ondansetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.89e-05	0.00164	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	7.87e-05	0.00164	CbGpPWpGaD
Ondansetron—Diarrhoea—Methotrexate—psoriasis	7.71e-05	0.000315	CcSEcCtD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.58e-05	0.00157	CbGpPWpGaD
Ondansetron—Dizziness—Methotrexate—psoriasis	7.45e-05	0.000304	CcSEcCtD
Ondansetron—HTR4—GPCR ligand binding—CXCL8—psoriasis	7.28e-05	0.00151	CbGpPWpGaD
Ondansetron—Vomiting—Methotrexate—psoriasis	7.16e-05	0.000292	CcSEcCtD
Ondansetron—Rash—Methotrexate—psoriasis	7.1e-05	0.00029	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—psoriasis	7.1e-05	0.00029	CcSEcCtD
Ondansetron—Headache—Methotrexate—psoriasis	7.06e-05	0.000288	CcSEcCtD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.88e-05	0.00143	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	6.86e-05	0.00143	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.59e-05	0.00137	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HCAR2—psoriasis	6.58e-05	0.00137	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CCL20—psoriasis	6.37e-05	0.00132	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NDUFA5—psoriasis	6.35e-05	0.00132	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	5.9e-05	0.00122	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HCAR2—psoriasis	5.8e-05	0.00121	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL20—psoriasis	5.78e-05	0.0012	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TAGAP—psoriasis	5.7e-05	0.00118	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.69e-05	0.00118	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CCL20—psoriasis	5.62e-05	0.00117	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.48e-05	0.00114	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP2S1—psoriasis	5.4e-05	0.00112	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—IL6—psoriasis	5.37e-05	0.00112	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.31e-05	0.0011	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.26e-05	0.00109	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL20—psoriasis	5.1e-05	0.00106	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TAGAP—psoriasis	5.03e-05	0.00105	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CXCL8—psoriasis	5.03e-05	0.00104	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HCAR2—psoriasis	5.01e-05	0.00104	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.97e-05	0.00103	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—JUN—psoriasis	4.94e-05	0.00103	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CCL20—psoriasis	4.85e-05	0.00101	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	4.76e-05	0.000988	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.76e-05	0.000988	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NDUFA5—psoriasis	4.6e-05	0.000955	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NDUFA5—psoriasis	4.59e-05	0.000953	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SOCS1—psoriasis	4.5e-05	0.000935	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	4.44e-05	0.000921	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL20—psoriasis	4.41e-05	0.000915	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TAGAP—psoriasis	4.34e-05	0.000902	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.32e-05	0.000896	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—TYK2—psoriasis	4.29e-05	0.000892	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.26e-05	0.000885	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.26e-05	0.000885	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CXCL8—psoriasis	4.12e-05	0.000855	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4e-05	0.00083	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP2S1—psoriasis	3.91e-05	0.000812	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP2S1—psoriasis	3.9e-05	0.000811	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCL8—psoriasis	3.83e-05	0.000795	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCL8—psoriasis	3.74e-05	0.000776	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—TNF—psoriasis	3.7e-05	0.000768	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.53e-05	0.000732	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL20—psoriasis	3.42e-05	0.00071	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—APOE—psoriasis	3.32e-05	0.00069	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—LEP—psoriasis	3.32e-05	0.00069	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NDUFA5—psoriasis	3.26e-05	0.000678	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NDUFA5—psoriasis	3.24e-05	0.000672	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NFKBIA—psoriasis	3.1e-05	0.000643	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.04e-05	0.000632	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCL8—psoriasis	3.04e-05	0.000632	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.02e-05	0.000627	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL20—psoriasis	3.02e-05	0.000626	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL6—psoriasis	2.98e-05	0.00062	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP2S1—psoriasis	2.78e-05	0.000576	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000574	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP2S1—psoriasis	2.75e-05	0.000571	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCL8—psoriasis	2.69e-05	0.000558	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CARM1—psoriasis	2.64e-05	0.000548	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL20—psoriasis	2.6e-05	0.00054	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.58e-05	0.000535	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TYK2—psoriasis	2.54e-05	0.000527	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000488	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCL8—psoriasis	2.32e-05	0.000481	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCL8—psoriasis	2.21e-05	0.000459	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NDUFA5—psoriasis	2.13e-05	0.000443	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—IL6—psoriasis	2.1e-05	0.000436	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—JUN—psoriasis	2.05e-05	0.000426	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NFKB1—psoriasis	1.98e-05	0.00041	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CARM1—psoriasis	1.91e-05	0.000397	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CARM1—psoriasis	1.91e-05	0.000396	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SOCS1—psoriasis	1.88e-05	0.000391	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP2S1—psoriasis	1.81e-05	0.000377	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—TYK2—psoriasis	1.79e-05	0.000373	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VEGFA—psoriasis	1.79e-05	0.000372	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—STAT3—psoriasis	1.78e-05	0.000369	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	1.72e-05	0.000357	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.66e-05	0.000345	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CAT—psoriasis	1.62e-05	0.000337	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.58e-05	0.000329	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL8—psoriasis	1.56e-05	0.000324	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.52e-05	0.000315	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.44e-05	0.000299	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SOCS1—psoriasis	1.43e-05	0.000298	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—LEP—psoriasis	1.39e-05	0.000288	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—APOE—psoriasis	1.39e-05	0.000288	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.38e-05	0.000286	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—TYK2—psoriasis	1.37e-05	0.000284	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CARM1—psoriasis	1.36e-05	0.000281	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—psoriasis	1.36e-05	0.000281	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CARM1—psoriasis	1.34e-05	0.000279	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	1.31e-05	0.000272	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKBIA—psoriasis	1.29e-05	0.000269	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—APOE—psoriasis	1.26e-05	0.000262	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000261	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—psoriasis	1.24e-05	0.000258	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.000256	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—LEP—psoriasis	1.23e-05	0.000254	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APOE—psoriasis	1.23e-05	0.000254	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—psoriasis	1.19e-05	0.000247	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CAT—psoriasis	1.17e-05	0.000244	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CAT—psoriasis	1.17e-05	0.000243	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CARM1—psoriasis	1.15e-05	0.000238	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKBIA—psoriasis	1.14e-05	0.000237	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—psoriasis	1.1e-05	0.000228	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000223	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TYK2—psoriasis	1.06e-05	0.00022	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—LEP—psoriasis	1.06e-05	0.00022	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOE—psoriasis	1.06e-05	0.00022	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKBIA—psoriasis	9.85e-06	0.000205	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TYK2—psoriasis	9.35e-06	0.000194	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—psoriasis	9.23e-06	0.000192	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOE—psoriasis	9.13e-06	0.00019	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOE—psoriasis	9.11e-06	0.000189	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CARM1—psoriasis	8.86e-06	0.000184	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—psoriasis	8.77e-06	0.000182	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—psoriasis	8.58e-06	0.000178	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CAT—psoriasis	8.34e-06	0.000173	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CAT—psoriasis	8.26e-06	0.000172	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKB1—psoriasis	8.26e-06	0.000171	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—psoriasis	8.14e-06	0.000169	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TYK2—psoriasis	8.07e-06	0.000168	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—psoriasis	7.95e-06	0.000165	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—psoriasis	7.93e-06	0.000165	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—psoriasis	7.74e-06	0.000161	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—psoriasis	7.57e-06	0.000157	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—psoriasis	7.49e-06	0.000156	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—psoriasis	7.42e-06	0.000154	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKB1—psoriasis	7.29e-06	0.000151	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CAT—psoriasis	7.06e-06	0.000147	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—psoriasis	7.03e-06	0.000146	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—psoriasis	6.68e-06	0.000139	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—psoriasis	6.61e-06	0.000137	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—psoriasis	6.55e-06	0.000136	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—psoriasis	6.53e-06	0.000136	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOE—psoriasis	6.48e-06	0.000135	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOE—psoriasis	6.42e-06	0.000133	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKB1—psoriasis	6.29e-06	0.000131	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—psoriasis	5.71e-06	0.000119	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—psoriasis	5.66e-06	0.000118	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—psoriasis	5.65e-06	0.000117	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—psoriasis	5.64e-06	0.000117	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—psoriasis	5.59e-06	0.000116	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOE—psoriasis	5.49e-06	0.000114	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CAT—psoriasis	5.45e-06	0.000113	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—psoriasis	5.18e-06	0.000108	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—psoriasis	5e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—psoriasis	4.78e-06	9.93e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—psoriasis	4.57e-06	9.5e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—psoriasis	4.31e-06	8.96e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOE—psoriasis	4.23e-06	8.8e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—psoriasis	3.95e-06	8.2e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—psoriasis	3.69e-06	7.66e-05	CbGpPWpGaD
